HeartFlow Surges 35.7% on 48% Revenue Growth, Raised Guidance

HeartFlow Inc (HTFL) told investors on its Q2 2026 earnings call that revenue rose 48% and gross margin expanded to 83.3%, and raised full-year guidance after Plaque revenue beat expectations; the shares closed at 42.08, up 35.70% on the day.

HeartFlow Inc (HTFL) gave the market the rarest combination in medical technology this earnings season: accelerating top-line growth, software-like gross margins, and enough confidence in the second half to lift full-year guidance. Investors responded in the only way that matters. The shares closed at 42.08, up 35.70% on the day from a prior close of 31.01, and traded as high as 43.00 during the session, according to market data as of 20:00 GMT on Friday, 14 August 2026.

The move stood in sharp relief against a flat broad tape. The S&P 500 tracker closed at $776.34, down 0.20%, the Nasdaq 100 proxy at $731.07, off 0.14%, and the Dow 30 fund at $536.80, lower by 0.21%. On a day when the major benchmarks did nothing, a single mid-cap medical technology name added better than a third of its market value.

What the quarter actually said

The headline numbers from the Q2 2026 call, as reported by GuruFocus, are three: revenue grew 48%, gross margin expanded to 83.3%, and management raised full-year guidance. A fourth detail is the one that explains the other three — revenue from the company’s Plaque product beat expectations.

Take the margin first, because it is the least discussed and the most structurally important. Gross margin is what is left of each dollar of revenue after the direct cost of delivering the product. At 83.3%, HeartFlow is operating closer to an enterprise software company than to a conventional device maker that has to manufacture, sterilise, ship and stock physical inventory. That is the economic signature of an analysis service: the underlying input is a scan that the hospital has already performed, and the deliverable is a computed result.

Margins at that level change the arithmetic of growth. Every incremental case processed drops a large share of its revenue straight toward operating profit, which means the path from rapid revenue expansion to genuine cash generation is shorter than it would be for a hardware business growing at the same rate. It also means the company can fund a commercial build-out — sales representatives, clinical education, payer engagement — without the gross margin line collapsing under it.

Why Plaque is the number to track

Growth of 48% is impressive in isolation, but the composition matters more than the rate. The lead detail from the call is that Plaque revenue came in ahead of expectations. That is a statement about adoption of a newer offering rather than deeper penetration of an established one, and the two have very different half-lives.

Deeper penetration of a mature product eventually runs into the ceiling of the addressable base. A newer product line beating internal forecasts suggests the company is still in the phase where each quarter adds accounts rather than merely adding volume within existing accounts. That is the phase in which guidance raises tend to cluster, because the forecast model has not yet caught up with the slope of the adoption curve.

The open question — and it is genuinely open — is whether that slope holds. Cardiac imaging analysis adoption depends on three things that move at different speeds: clinical evidence, reimbursement, and workflow integration inside hospitals that are chronically short of staff. Evidence and reimbursement can move in a company’s favour and still leave the bottleneck at the third. Sustaining 48% growth requires all three to keep clearing.

How to read a 35.70% single-session move

A move of that magnitude is not a re-rating for a 48% revenue print alone. Markets generally price in growth for a company already known to be growing. What they do not price is a change in the trajectory of expectations — and a guidance raise driven by a product beating plan is exactly that.

The mechanics of the session tell their own story. The day’s low was 36.04, well above the prior close of 31.01, indicating the stock gapped higher at the open and never traded back to the previous session’s level. It then worked its way to 43.00 before settling at 42.08, near the upper end of the range. Closing in the top portion of a wide up-day range is generally read as buyers, not short-covering exhaustion, controlling the tape into the bell — though a single session proves nothing on its own.

One caution on the quote itself: the market data feed for HTFL did not specify the listing exchange or the trading currency, so the figures above are stated as they were supplied. Readers checking the position should confirm the listing venue before acting.

The questions the next two quarters have to answer

Three things will determine whether this re-rating holds.

• Does the margin stay at 83.3%? A gross margin that expands during a period of rapid volume growth suggests operating leverage rather than mix luck. If it slips as the company scales into lower-priced accounts or new geographies, the equity story changes materially.
• Is the guidance raise conservative or stretched? The size and shape of the new full-year range — and whether management framed it as capturing the Q2 beat only, or as reflecting a higher run-rate for the second half — determines how much room is left for further upside surprise.
• Does Plaque growth broaden? Growth concentrated in a handful of large accounts is fragile. Growth spread across new sites is durable. The account-count disclosure, not the revenue line, is the tell.

There is also the matter of what sits below the gross margin line. An 83.3% gross margin is only valuable if operating expenses grow more slowly than revenue. Companies in the land-grab phase of a new category frequently spend the entire gross profit and more on commercial expansion — a defensible choice, but one that keeps the profitability question deferred rather than answered.

The wider setting

The reaction says something about where investor appetite currently sits. With the broad indices essentially unchanged and drifting slightly lower on the day, capital rewarded a specific, verifiable acceleration rather than a thematic story. That is characteristic of a market in which the index level is not doing the work and returns have to be found in individual results.

For HeartFlow, the burden has now shifted. A stock that closed 35.70% higher has already banked the beat and much of the raise. From here, meeting the new guidance is the baseline expectation, not the upside case — and holding an 83.3% gross margin while growing anywhere near 48% is what the current price is asking for.

Key facts

• HTFL last close: 42.08, +35.70% (as of 20:00 GMT, 14 Aug 2026)
• Revenue growth: 48% in Q2 2026
• Gross margin: 83.3%, expanded in the quarter
• Guidance: Full-year outlook raised on Plaque revenue beat

Frequently asked questions

What did HeartFlow report in Q2 2026?

HeartFlow reported revenue growth of 48% for the second quarter of 2026, with gross margin expanding to 83.3%. Revenue from its Plaque product came in ahead of expectations, and management raised full-year guidance on the earnings call. The combination of accelerating growth, margin expansion and a raised outlook drove a sharp move in the shares.

How much did HTFL stock move?

HTFL closed at 42.08, up 35.70% from a prior close of 31.01, based on market data as of 20:00 GMT on 14 August 2026. The day range ran from 36.04 to 43.00, meaning the stock gapped above the previous close at the open and finished near the upper end of its session range.

Why is an 83.3% gross margin significant?

Gross margin is the share of revenue left after the direct cost of delivering the product. At 83.3%, HeartFlow’s economics resemble a software business more than a traditional device maker with manufacturing and inventory costs. That means each additional case processed contributes heavily toward operating profit, shortening the path from revenue growth to cash generation.

What is driving HeartFlow’s growth?

The company’s Plaque product line was the specific driver called out on the Q2 2026 call, with revenue exceeding expectations. That points to new adoption rather than simply higher volumes within existing accounts, which is typically the phase in which a company’s internal forecasts lag the actual pace of uptake and guidance raises follow.

How did the broader market perform that day?

The major benchmarks were slightly lower. The S&P 500 tracker closed at $776.34, down 0.20%; the Nasdaq 100 proxy finished at $731.07, off 0.14%; and the Dow 30 fund ended at $536.80, down 0.21%. HeartFlow’s move therefore came against a flat-to-negative broad tape rather than a market-wide rally.

What should investors watch next from HeartFlow?

Three things: whether the 83.3% gross margin holds as volume scales, whether the raised full-year guidance proves conservative or stretched, and whether Plaque growth broadens across new accounts rather than concentrating in a few large ones. Operating expense growth relative to revenue will also determine when high gross margins translate into actual profitability.

Sources

• HeartFlow Inc (HTFL) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% and Plaque Momentum … — GuruFocus

Photo: Tima Miroshnichenko · Pexels Licence — source